Logo Logo

Publications by Verma, S.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 7.

Journal article

Turner, N. C.; Slamon, D. J.; Ro, J.; Bondarenko, I; Im, S-A; Masuda, N.; Colleoni, M.; DeMichele, A.; Loi, S.; Verma, S.; Iwata, H.; Harbeck, N.; Loibl, S.; Andre, F.; Puyana Theall, K.; Huang, X.; Giorgetti, C.; Huang Bartlett, C.; Cristofanilli, M. (2018): Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. In: New England Journal of Medicine, Vol. 379, No. 20: pp. 1926-1936

Dieras, V.; Harbeck, N.; Joy, A. A.; Gelmon, K. A.; Ettl, J.; Verma, S.; Lu, D.; Gauthier, E. R.; Schnell, P.; Mori, A.; Rugo, H. S.; Finn, R. S. (2017): PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) first-line advanced breast cancer (ABC) receiving palbociclib plus letrozole (P plus L). In: Annals of Oncology, Vol. 28

Baselga, J.; Cortés, J.; De Laurentiis, M.; Diéras, V.; Harbeck, N.; Hsu, J.; Jin, H.; Schimmoller, F.; Wilson, T. R.; Im, Y.-H.; Jacot, W.; Krop, I. E.; Verma, S. (2016): SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors. In: Cancer Research, Vol. 76

Verma, S.; DeMichele, A. M.; Loi, S.; Ro, J.; Colleoni, M.; Iwata, H.; Harbeck, N.; Stearns, V.; Cristofanilli, M.; Huang Bartlett, C.; Schnell, P.; Zhang, K.; Thiele, A.; Turner, N. C.; Rugo, H. S. (2016): Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. In: Cancer Research, Vol. 76

Harbeck, N.; Iyer, S.; Turner, N.; Cristofanilli, M.; Ro, J.; André, F.; Loi, S.; Verma, S.; Iwata, H.; Bhattacharyya, H.; Theall, K. Puyana; Bartlett, C. H.; Loibl, S. (2016): Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. In: Annals of Oncology, Vol. 27, No. 6: pp. 1047-1054

Loibl, S.; Demichele, A.; Turner, N. M.; Cristofanilli, M.; Loi, S.; Verma, S.; Bhattacharyya, H.; Ke, Z.; Giorgetti, C.; Bartlett, C. H.; Iyer, S.; Colleoni, M.; Masuda, N.; Im, S.-A.; Harbeck, N. (2016): Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR +, HER2-metastatic breast cancer. In: Annals of Oncology, Vol. 27

Baselga, J.; Cortes Castan, J.; De Laurentiis, M.; Dieras, V.; Harbeck, N.; Hsu, J.; Jin, H.; Schimmoller, F.; Wilson, T. R.; Im, Y.-H.; Jacot, W.; Krop, I. E.; Verma, S. (2016): SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours. In: Annals of Oncology, Vol. 27

This list was generated on Fri Dec 6 07:18:10 2019 CET.